ArticleFrontiers in oncology2025
Real world prevalence of pelvic lymph node involvement in prostate cancer in Asia: do we need a rethink on normograms?
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The Briganti 2019 nomogram stratifies risk of lymph node involvement (LNI) in prostate cancer, reducing unnecessary pelvic lymph node dissection (PLND) during radical prostatectomy (RP). However the applicability of the nomogram in diverse populations remains under-explored, with only one external validation study performed in an Asian population to date. We aim to evaluate the performance of the nomogram in a large tertiary Asian institution. Methods: A retrospective cohort study was conducted, with analysis of the cancer registry in our tertiary institution of all patients who underwent RP with PLND between 1988 and 2023. The Briganti 2019 nomogram score was retrospectively calculated for each patient, and post-operative data was analyzed to determine rates of LNI in order to determine the performance of the nomogram in our cohort. Results: 437 patients were included, with a median Briganti score of 11.2% (IQR 3.9-28.5%). The mean number of lymph nodes excised per patient was 15.1±12. 292 (66.8%) patients had a Briganti score greater than 7%, but only 8.6% were noted to harbor pN1 disease after RP. In our Asian cohort, the 2019 Briganti nomogram only had a moderate discriminatory ability with an area under the receiver operating characteristic curve (AUC) of 0.77. On multivariate analysis, independent predictors of LNI in our population included percentage of positive biopsy cores [Odds Ratio (OR) 1.02, 95%CI 1.01-1.04, p=0.01] and extraprostatic extension on MRI prostate (OR 3.00, 95%CI 1.20-7.56, p=0.02). Conclusion: The Briganti 2019 nomogram, while effective in many settings, only had a moderate ability to identify patients with pN1 disease in our Asian cohort. With potential limitations in its generalizability to multiple populations, a re-evaluation of its thresholds and further calibration to other populations might be required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.